Full Text View
Tabular View
No Study Results Posted
Related Studies
In Vivo Angiostatin Generation Using Tissue Plasminogen Activator and Captopril in Treating Patients With Progressive Metastatic Cancer
This study is ongoing, but not recruiting participants.
Study NCT00086723   Information provided by National Cancer Institute (NCI)
First Received: July 8, 2004   Last Updated: February 6, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Neoplasm Metastasis
More general conditions related to this trial
Neoplasms
Neoplastic Processes
Pathologic Processes
Interventions listed in this trial
captopril
Additional drug interventions recognized in this trial
Angiostatins
Plasminogen
Tissue Plasminogen Activator
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Antineoplastic Agents
Cardiovascular Agents
Enzyme Inhibitors
Fibrin Modulating Agents
Fibrinolytic Agents
Growth Inhibitors
Growth Substances
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Robert H. Lurie Cancer Center
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services